Shots:
- Merck KGaA has entered into a definitive agreement to acquire Bio-Techne, bringing together two companies with complementary portfolios spanning research tools, diagnostics, bioprocessing, and advanced therapeutics
- As per the deal, Merck KGaA will acquire Bio-Techne for $73/share in cash, representing a total enterprise value of ~$11.3B; closing is expected by late 2026 or early 2027
- Acquisition will strengthen Merck KGaA’s presence in high-growth areas incl. multi-omics, spatial biology, precision diagnostics, cell and gene therapy, and advanced research tools, with Bio-Techne’s portfolio complementing Merck’s life science offerings
Ref: PRnewswire | Image: Bio-Techne | Press Release
Related News: AbbVie to Acquire Apogee Therapeutics for ~$10.9B
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
